Notifications
Clear all
Topic starter
13/06/2020 1:49 am
http://www.koreabiomed.com/news/articleView.html?idxno=8283
"the researchers demonstrated that amivantamab's effect on the killing of cancer cells is deeply involved in antibody-dependent cell-mediated cytotoxicity using NK cells or macrophage in the patient's immune system."
